Results 21 to 30 of about 450,934 (396)
Atypical parkinsonism: An Update. [PDF]
, 2013 Purpose of review: This update discusses novel aspects on genetics, diagnosis, and treatments of atypical parkinsonism published over the past 2 years. Recent findings: A genome-wide association study identified new genetic risk factors for progressive ...
Hoeglinger, GU, Stamelou, M
core +1 more source
Cell & Bioscience, 2021 AbstractPatients with Parkinson’s disease (PD) exhibit systemic deficits, including arthritis and osteoporosis-like symptoms. However, the questions, how the deficits in periphery organs or tissues occur in PD patients, and what are the relationship (s) of the periphery tissue deficits with the brain pathology (e.g., dopamine neuron loss), are at the ...
Lei Xiong +7 more
openaire +4 more sources
Environmental Exposures and Parkinson's Disease. [PDF]
, 2016 Parkinson's disease (PD) affects millions around the world. The Braak hypothesis proposes that in PD a pathologic agent may penetrate the nervous system via the olfactory bulb, gut, or both and spreads throughout the nervous system. The agent is unknown,
Litvan, Irene, Nandipati, Sirisha
core +2 more sources
Drugs in R&D, 2019 Background and objectives Inhibition of Abelson (Abl) tyrosine kinase as a therapeutic target has been gaining attention in neurodegeneration. Post-mortem Alzheimer’s and Parkinson’s disease brains show that the levels of several other tyrosine kinases ...
Alan J. Fowler +7 more
doaj +1 more source
Study on drug-induced parkinsonism and its clinical patterns in Eastern Indian population
APIK Journal of Internal Medicine, 2023 Background: Drug-induced parkinsonism (DIP) is important as it is reversible if identified and treated early. We present herewith various clinical patterns and drugs commonly causing DIP.
Praveen Kumar Yadav
doaj +1 more source
Adrenal pheochromocytoma incidentally discovered in a patient with parkinsonism [PDF]
, 2015 To evaluate the diagnostic route of pheochromocytoma (PHEO) in a patient under dopaminergic treatment. A 70-year-old man with Parkinsonism and under treatment with levodopa and carbidopa came to our observation for evaluation of arterial hypertension and
Claudio Letizia +7 more
core +1 more source
EMBO Molecular Medicine, 2013 Tyrosine kinase inhibitors (TKIs) are effective therapies for leukaemia. Alzheimer is a neurodegenerative disease characterized by accumulation of β‐amyloid (plaques) and hyper‐phosphorylated Tau (tangles).
Irina Lonskaya +4 more
doaj +1 more source
X-linked Dystonia-Parkinsonism patient cells exhibit altered signaling via nuclear factor-kappa B
Neurobiology of Disease, 2017 X-linked Dystonia-Parkinsonism (XDP) is a progressive neurodegenerative disease involving the loss of medium spiny neurons within the striatum. An XDP-specific haplotype has been identified, consisting of seven sequence variants which cluster around the ...
Christine A. Vaine +7 more
doaj +1 more source
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets [PDF]
, 1992 The mixed dopamine (DA) agonist/antagonist terguride acts as a DA antagonist on normosensitive receptors but shows DA agonistic properties at supersensitive DA receptors.
Horowski, R. +6 more
core +1 more source
Neurobiology of Disease, 2020 Neuroinflammation plays a pathogenic role in neurodegenerative diseases and recent findings suggest that it may also be involved in X-linked Dystonia-Parkinsonism (XDP) pathogenesis.
Tiziana Petrozziello +16 more
doaj +1 more source